Marek K - Search Results

1

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.

Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson’s Progression Marker Initiative Authors. Simuni T, et al. Among authors: marek k. NPJ Parkinsons Dis. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. NPJ Parkinsons Dis. 2022. PMID: 36273008 Free PMC article.

2

The natural history of the syndrome of primary progressive freezing gait.

Factor SA, Jennings DL, Molho ES, Marek KL. Factor SA, et al. Arch Neurol. 2002 Nov;59(11):1778-83. doi: 10.1001/archneur.59.11.1778. Arch Neurol. 2002. PMID: 12433266

3

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.

Marek K, Jennings D, Seibyl J. Marek K, et al. Adv Neurol. 2003;91:183-91. Adv Neurol. 2003. PMID: 12442677 Review. No abstract available.

4

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.

Marek K, Jennings D, Seibyl J. Marek K, et al. Ann Neurol. 2003;53 Suppl 3:S160-6; discussion S166-9. doi: 10.1002/ana.10486. Ann Neurol. 2003. PMID: 12666107 Review. No abstract available.

5

Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.

Marek K, Jennings D, Seibyl J. Marek K, et al. Neurology. 2003 Sep 23;61(6 Suppl 3):S43-8. doi: 10.1212/wnl.61.6_suppl_3.s43. Neurology. 2003. PMID: 14504379 Review. No abstract available.

6

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Fahn S, et al. Among authors: marek k. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Free article. Clinical Trial.

7

Role of DAT-SPECT in the diagnostic work up of parkinsonism.

Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W. Scherfler C, et al. Among authors: marek k. Mov Disord. 2007 Jul 15;22(9):1229-38. doi: 10.1002/mds.21505. Mov Disord. 2007. PMID: 17486648 Review.

8

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease.

Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB. Siderowf A, et al. Among authors: marek k. Mov Disord. 2007 Nov 15;22(15):2249-55. doi: 10.1002/mds.21707. Mov Disord. 2007. PMID: 17876851

9

Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.

Marek K, Jennings D, Tamagnan G, Seibyl J. Marek K, et al. Ann Neurol. 2008 Dec;64 Suppl 2:S111-21. doi: 10.1002/ana.21602. Ann Neurol. 2008. PMID: 19127587

10

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators. Ravina B, et al. Among authors: marek k. Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690. Mov Disord. 2009. PMID: 19691116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

454 results

Search Page

Filters